Applied DNA Sciences Files 8-K on Financials
Ticker: BNBX · Form: 8-K · Filed: Feb 13, 2025 · CIK: 744452
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: APDN
TL;DR
APDN filed an 8-K on Feb 13, 2025, detailing financial results. Check it out.
AI Summary
Applied DNA Sciences, Inc. filed an 8-K on February 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's fiscal year ending on September 30th. Applied DNA Sciences, Inc. is incorporated in Delaware and its principal business address is 50 Health Sciences Drive, Stony Brook, NY.
Why It Matters
This filing provides investors with an update on the company's financial performance and condition, which is crucial for evaluating its current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — Registrant
- February 13, 2025 (date) — Date of earliest event reported
- 50 Health Sciences Drive (location) — Business Address
- Stony Brook, NY (location) — Business Address City and State
- Delaware (location) — State of Incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Applied DNA Sciences, Inc., and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 13, 2025.
In which state is Applied DNA Sciences, Inc. incorporated?
Applied DNA Sciences, Inc. is incorporated in Delaware.
What is the business address of Applied DNA Sciences, Inc.?
The business address of Applied DNA Sciences, Inc. is 50 Health Sciences Drive, Stony Brook, NY 11790.
What is the fiscal year end for Applied DNA Sciences, Inc.?
The fiscal year end for Applied DNA Sciences, Inc. is September 30th.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-02-13 16:05:34
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- tm256524d1_8k.htm (8-K) — 25KB
- tm256524d1_ex99-1.htm (EX-99.1) — 113KB
- tm256524d1_ex99-1img001.jpg (GRAPHIC) — 22KB
- 0001104659-25-012921.txt ( ) — 350KB
- apdn-20250213.xsd (EX-101.SCH) — 3KB
- apdn-20250213_lab.xml (EX-101.LAB) — 33KB
- apdn-20250213_pre.xml (EX-101.PRE) — 22KB
- tm256524d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 13, 2025, Applied DNA Sciences, Inc. ("Applied DNA Sciences" or the "Company") issued a press release announcing its results of operations for the three-month period ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. ( d) Exhibits 99.1 Press Release of Applied DNA Sciences, Inc. dated February 13, 2025 regarding results of operations for the three-month period December 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 13, 2025 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer